secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001628280-24-040396
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio and ImmuneOnco outline global registrational strategy for SYN-2510 in NSCLC and TNBC
--------------------------------------------------------------------------------

- Global registrational strategy for SYN-2510/IMM2510 in front-line NSCLC and TNBC announced.
- Phase 1b/2 chemo combo in front-line NSCLC expected to start late 2024 in China; US IND submission for SYN-2510 targeted late 2024 for Phase 2 monotherapy in second-line NSCLC.
- Phase 1b/2 chemo combo in front-line TNBC expected to start early 2025 in China; potential global Phase 3 trials after proof-of-concept.
- US Phase 2 monotherapy trial in second-line NSCLC expected to support efficient enrollment of global Phase 3 studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000162828024040396/0001628280-24-040396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000162828024040396/til-20240916.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-040396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer